Bernard Poussot: The ongoing Phase III program is advancing. In most cases, we have resumed activities XUS. In most countries a couple of situations still need to be addressed but we are confident that within weeks we will be back in full gear in those countries. The North American portion is progressing accordingly and we are pleased and continue to hope for the original timing that we had for Bapineuzumab.